OPTN Insider Trading

Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $261,223.65

OptiNose Insider Trading History Chart

This chart shows the insider buying and selling history at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k$0$200kTotal Insider BuyingTotal Insider Selling

OptiNose Share Price & Price History

Current Price: $9.14
Price Change: Price Decrease of -0.03 (-0.33%)
As of 04/1/2025 03:11 PM ET

This chart shows the closing price history over time for OPTN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$9.17Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for OptiNose (NASDAQ:OPTN)

85.60% of OptiNose stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OPTN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.86Mbought$515MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More on OptiNose

Today's Range

Now: $9.14
Low: $9.10
High: $9.19

50 Day Range

MA: $6.36
Low: $5.27
High: $9.17

52 Week Range

Now: $9.14
Low: $4.82
High: $22.35

Volume

90,263 shs

Average Volume

63,262 shs

Market Capitalization

$91.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of OptiNose?

OptiNose's top insider shareholders include:
  1. Ramy A Mahmoud (CEO)
  2. Michael F Marino III (Insider)
  3. Paul Jr Spence (Insider)
  4. Anthony J Krick (CAO)
Learn More about top insider investors at OptiNose.

Who are the major institutional investors of OptiNose?

OptiNose's top institutional shareholders include:
  1. Nantahala Capital Management LLC — 9.80%
  2. MVM Partners LLC — 9.68%
  3. Rosalind Advisors Inc. — 8.72%
  4. Stonepine Capital Management LLC — 5.85%
  5. Acorn Capital Advisors LLC — 4.20%
  6. D. E. Shaw & Co. Inc. — 3.31%
Learn More about top institutional investors of OptiNose stock.

Which major investors are selling OptiNose stock?

During the previous quarter, OPTN stock was sold by these institutional investors:
  1. MVM Partners LLC
  2. Nantahala Capital Management LLC
  3. Rosalind Advisors Inc.
  4. Stonepine Capital Management LLC
  5. D. E. Shaw & Co. Inc.
  6. Bleichroeder LP
  7. Easterly Investment Partners LLC
  8. Geode Capital Management LLC
During the previous year, company insiders that have sold OptiNose company stock include:
  1. Ramy A Mahmoud (CEO)
  2. Michael F Marino III (Insider)
  3. Paul Jr Spence (Insider)
  4. Anthony J Krick (CAO)
Learn More investors selling OptiNose stock.

Which major investors are buying OptiNose stock?

During the last quarter, OPTN stock was purchased by institutional investors including:
  1. Acorn Capital Advisors LLC